DcR3 mutations in patients with juvenile-onset systemic lupus erythematosus lead to enhanced lymphocyte proliferation

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1316-1326

  Chokdeemeeboon, Chayanin ^a,b   Ammarinthnukrowh, Pramuk ^a,b   Tongkobpetch, Siraprapa ^a,b   Srichomtong, Chalurmpon ^b,c   Deekajorndech, Tawatchai ^b   Rianthavorn, Pornpimol ^b   Kingwattanakul, Pornchai ^b   Avihingsanon, Yingyos ^b   Wright, Helen L ^d   Akkahat, Piyaporn ^b   Hoven, Voravee P ^b   Mekboonsonglarp, Wanwimon ^b   Edwards, Steven W ^d   Hirankarn, Nattiya ^b   Suphapeetiporn, Kanya ^b,c   Shotelersuk, Vorasuk ^b,c  

^a Faculty of Graduate School   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Affinity; Apoptosis; Death decoy receptor 3; Proliferation; Systemic lupus erythematosus

Indexed keywords

CYTOSINE; DEATH DECOY RECEPTOR 3; FAS LIGAND; HISTIDINE; RECOMBINANT PROTEIN; THYMINE; TUMOR NECROSIS FACTOR RECEPTOR; TYROSINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DCR3 GENE; DEATH DECOY RECEPTOR 3 BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE; GENE SEQUENCE; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; JUVENILE; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX; SYSTEMIC LUPUS ERYTHEMATOSUS;

AFFINITY; APOPTOSIS; DEATH DECOY RECEPTOR 3; PROLIFERATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84881409620     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121285     Document Type: Article

References (26)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21.
2. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
3. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479-92.
4. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274:13733-6.
5. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30:180-92.
6. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, Kwon BS, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-51.
7. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Nat Acad Sci USA 2000;97:1230-5.
8. Wan X, Shi G, Semenuk M, Zhang J, Wu J. DcR3/TR6 modulates immune cell interactions. J Cell Biochem 2003;89:603-12.
9. Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008;151:383-90.
10. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 2002;100:3279-86.
11. Wan X, Zhang J, Luo H, Shi G, Kapnik E, Kim S, et al. A TNF family member LIGHT transduces costimulatory signals into human T cells. J Immunol 2002;169:6813-21.
12. Han B, Moore PA, Wu J, Luo H. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum 2007;56:3748-58.
13. Han B, Bojalil R, Amezcua-Guerra LM, Springall R, Valderrama-Carvajal H, Wu J, et al. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int Immunol 2008;20:1067-75.
14. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al. Disease activity, severity, and damage in the UK Juvenile-onset SLE Cohort. Arthritis Rheum 2012;64:2356-65.
15. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus: Different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009;68:412-5.
16. Chiang LL, Lin YT, Chan HY, Chiang BL. Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 Chinese children and adolescents. Pediatr Rheumatol Online J 2012;10:12.
17. Mina R, Brunner HI. Pediatric lupus-Are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010;36:53-80, vii-viii.
18. Balow JE, Austin HA 3rd, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH. Lupus nephritis. Ann Intern Med 1987;106:79-94.
19. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
20. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808.
21. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000;5:443-9.
22. Levine JS, Koh JS. The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant. Semin Nephrol 1999;19:34-47.
23. Alarcon-Segovia D, Llorente L, Ruiz-Arguelles A. The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. J Autoimmun 1996;9:295-300.
24. Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-8.
25. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, et al. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997;132:1263-70.
26. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009;58:483-91.